Biological Agents in the Treatment of Atopic Dermatitis and Atopic Comorbidities： A Review and Update

VernacularTitle:生物制剂治疗特应性皮炎和特应性共病的研究进展
Author: Pei-ying FENG ¹
Author Information

1. Department of Allergy， The Third Affiliated Hospital， Sun Yat-sen University， Guangzhou 510630， China
Publication Type:Journal Article
Keywords: atopic dermatitis; atopic march; atopic comorbidities; biological agents
From: Journal of Sun Yat-sen University(Medical Sciences) 2022;43(1):1-9
CountryChina
Language:Chinese
Abstract: Atopic dermatitis （AD） is the most common chronic inflammatory skin disease characterized by relapsing pruritic eczema-like lesion and induced by genetic predisposition， epidermal barrier disruption and dysregulation of the immune system. AD is a complex and systemic disorder associated with a variety of clinical features. Patients with AD are at risk of developing atopic comorbidities， such as food allergy， allergic rhinitis， asthma and allergic conjunctivitis etc. AD and its comorbidities may share a common pathogenic pathway， so biological agents designed to inhibit specific molecular targets of immune responses can have an impact on comorbidities by changing inflammatory state. This review summarizes the research progress of the biotherapy in the treatment of AD and atopic comorbidities.